Lobe Sciences to Present Phase 1a Low-Dose Psilocin Data for L-130 at Neuropsychiatric Drug Development Summit
核心洞察
Lobe Sciences will present Phase 1a first-in-human data for Conjugated Psilocin (L-130) at the 9th Neuropsychiatric Drug Development Summit in Boston on September 16, 2026.
The ten-subject Phase 1a results cover oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses of the patented psilocin salt.
L-130 is a patented new chemical entity delivering psilocin directly rather than as a prodrug, initially developed for cluster headache (搜索) with co-development in PTSD (搜索) and other disorders.
Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) will present clinical and preclinical data for its lead CNS asset Conjugated Psilocin™ (L-130) at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston, Massachusetts, the clinical-stage biopharmaceutical company announced.
Dr. Frederick D. Sancilio, Chairman and Chief Executive Officer, will deliver the presentation, titled "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm," at 11:00 a.m. ET on Wednesday, September 16 in the summit's preclinical and translational track.
Phase 1a Data and Formulation Strategy
The presentation sets out the case for patented L-130 as a candidate suited to daily outpatient dosing rather than the supervised in-clinic administration that psychedelic-class candidates typically require. It covers the compound's formulation characteristics as a patented salt of psilocin — the active moiety itself rather than a prodrug — together with first-in-human results in ten subjects showing consistent oral pharmacokinetics, and preclinical findings on daily low-dose administration.
According to the company, the Phase 1a data include oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses.
Targeting Predictable Psilocin Exposure
Lobe describes L-130 as a patented new chemical entity initially being developed for cluster headache (搜索), with co-development programs underway for PTSD (搜索), substance use disorder (搜索), generalized anxiety disorder (搜索), and other neuropsychiatric disorders.
Unlike conventional psilocybin, which produces highly variable psilocin exposure between patients, L-130 is designed to deliver psilocin directly with a predictable pharmacokinetic profile. The company's development strategy is built on the premise that the therapeutic benefits of psilocin may be achieved at controlled exposure levels below those typically associated with hallucinations — potentially separating efficacy from the psychedelic experience and substantially expanding the clinical and commercial potential of psychedelic-derived medicines.
Additional Pipeline and Summit Presence
Lobe is also advancing S-100 (搜索), a novel therapeutic for sickle cell disease (搜索), with Phase 3 clinical development anticipated to commence in mid-2027.
The company will exhibit throughout the three-day summit, which brings together senior discovery, translational, clinical, regulatory and business development leaders from large pharmaceutical companies, biotechnology companies and investors active in neuropsychiatric drug development.
Early-Stage Caveats
In its forward-looking statement, Lobe cautioned that early-stage clinical and preclinical results are not necessarily predictive of results in later-stage studies, and that observations in a small number of subjects or in animal models may not be reproduced in larger human populations. The company also noted that no regulatory authority has approved L-130 for any indication.